Specify Company / Ticker to Get the Summary
Amicus Therapeutics Inc
FOLDAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Address: 47 Hulfish Street, Princeton, NJ, United States, 08542
Analytics
WallStreet Target Price
17.75 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures FOLD
Dividend Analytics FOLD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FOLD
Stock Valuation FOLD
Financials FOLD
Results | 2019 | Dynamics |